Lina, Bruno and Boucher, Charles and Osterhaus, Albert and Monto, Arnold S. and Schutten, Martin and Whitley, Richard J. and Nguyen-Van-Tam, Jonathan S. (2018) Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study (IRIS). Influenza and Other Respiratory Viruses. ISSN 1750-2659

Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/48180/89/Lina_et_al-2018-Influenza_and_Other_Respiratory_Viruses.pdf

Copyright and reuse:

The Nottingham ePrints service makes this work by researchers of the University of Nottingham available open access under the following conditions.

This article is made available under the Creative Commons Attribution licence and may be reused according to the conditions of the licence. For more details see: http://creativecommons.org/licenses/by/2.5/

A note on versions:

The version presented here may differ from the published version or from the version of record. If you wish to cite this item you are advised to consult the publisher’s version. Please see the repository url above for details on accessing the published version and note that access may require a subscription.

For more information, please contact eprints@nottingham.ac.uk
Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study

Bruno Lina | Charles Boucher | Albert Osterhaus | Arnold S. Monto
Martin Schutten | Richard J. Whitley | Jonathan S. Nguyen-Van-Tam

1Lab Virology HCL & CIRI INSERM U1111, Université de Lyon, Lyon, France
2Erasmus MC, Rotterdam, The Netherlands
3Research Institute for Emerging Infections and Zoonoses Veterinary University Hannover, Hannover, Germany
4University of Michigan School of Public Health, Ann Arbor, MI, USA
5University of Alabama at Birmingham, Birmingham, AL, USA
6Health Protection and Influenza Research Group, University of Nottingham School of Medicine, Nottingham, UK

Correspondence
Bruno Lina, Laboratoire de Virologie, CNR des Virus Influenza, HCL & Laboratoire Virpath, CIRI Inserm U1111, CNRS 5308, ENS, UCBL, Faculté de Médecine LYON Est, Université de Lyon, Lyon, France.
Email: bruno.lina@chu-lyon.fr

Funding information
The IRIS study was funded by F. Hoffmann-La Roche Ltd.

Background and objectives: The Influenza Resistance Information Study (IRIS) was initiated in 2008 to study the emergence of neuraminidase inhibitor (NAI) resistance and the clinical course of influenza in immunocompetent treated and untreated patients.

Methods: Patients had throat/nose swabs collected on days 1, 3, 6 and 10 for analyses of influenza type, subtype and virus susceptibility to NAIs. RT-PCR-positive samples were cultured and tested for NAI resistance by specific RT-PCR and phenotypic testing. Scores for influenza symptoms were recorded on diary cards (Days 1-10). This study focuses on influenza A-infected cases only.

Results: Among 3230 RT-PCR-positive patients, 2316 had influenza A of whom 1216 received oseltamivir monotherapy within 2 days of symptom onset (9 seasonal H1N1; 662 H3N2; 545 H1N1pdm2009). Except for 9 patients with naturally resistant seasonal H1N1 (2008/9), no resistance was detected in Day 1 samples. Emergence of resistance (post-Day 1) was detected in 43/1207 (3.56%) oseltamivir-treated influenza A-infected patients, with a higher frequency in 1- to 5-year-olds (11.8%) vs >5-year-olds (1.4%). All N1- and N2-resistant viruses had H275Y (n = 27) or R292K (n = 16) substitutions, respectively. For 43 patients, virus clearance was significantly delayed vs treated patients with susceptible viruses (8.1 vs 10.9 days; $P < .0001$), and 11 (23.2%) remained RT-PCR positive for influenza at Day 10. However, their symptoms resolved by Day 6 or earlier.

Conclusions: Oseltamivir resistance was only detected during antiviral treatment, with the highest incidence occurring among 1- to 5-year-olds. Resistance delayed viral clearance, but had no impact on symptom resolution.

KEYWORDS
antiviral, influenza, neuraminidase inhibitor, resistance

1 INTRODUCTION

Neuraminidase inhibitors (NAIs) are the mainline therapy of influenza.$^1$ Through binding in the conserved catalytic domain of the enzyme, these drugs can inhibit all types and subtypes of influenza neuraminidase, but to varying degrees.$^2$ In recent years, the human influenza A viruses have developed complete resistance to an older class of drugs, the adamantanes, indicating the ability of these viruses to develop
and subsequently maintain resistance to antivirals. In the first years of NAI use, following their introduction in 1999, naturally occurring resistance was sporadically reported and a very limited number of cases were described. However, in 2008, naturally occurring oseltamivir resistance was detected among seasonal H1N1 viruses in Norway. This resistant virus eventually displaced the NAI-susceptible H1N1 virus rendering virtually all seasonal H1N1 viruses highly resistant to oseltamivir. This emergence was not related to the use of antivirals. The resistant H1N1 virus was then replaced during the 2009-2010 pandemic by the influenza A H1N12009pdm virus, which was oseltamivir sensitive.

As a consequence of this emergence and dissemination of an NAI-resistant virus, surveillance systems have been implemented to monitor antiviral susceptibility to NAI. In this context, a global observational study was initiated in 2008, the Influenza Resistance Information Study (IRIS), to study the emergence of NAI resistance and the clinical course of influenza in immunocompetent treated and untreated patients.

The primary objective of the IRIS study was to assist with early detection of influenza resistance to antivirals and describe the clinical course and outcome of patients with influenza according to subtype and antiviral susceptibility.

Influenza Resistance Information Study is a prospective, multicentre, information-gathering study (NCT00884117). It is the largest study of its type that has collected sequential clinical and virological data during the course of infection, using sensitive RT-PCR detection methods for both detection of the virus and follow-up of substitutions associated with oseltamivir resistance in H1N1 and H3N2 viruses. Major findings of the first 3 years of this study have already been reported.

This article reports the first 5 years of surveillance carried out through IRIS, with a specific focus on the description of the emergence of influenza A-resistant viruses in treated patients, including the timeline of the emergence of the resistant viruses and the identification of the substitutions associated with this resistance.

## MATERIAL AND METHODS

### 2.1 Study design and conduct

Influenza Resistance Information Study (IRIS; NCT00884117) is a 7-year prospective, multicentre, observational study. Recruitment started in December 2008 (Year 1), continued throughout the 2009-10 A/H1N1 influenza pandemic and until March 2013 (Year 5). After the 5th season, the study design was modified to continue for 2 additional years (Years 6 and 7 until March 2015) with a different objective (focus on immunocompromised children only).

During the first 5 years of the study, inclusion centres were located in Europe (France, Germany, Norway, Poland), USA, China (Hong Kong) and Australia. Enrolment was carried out during 5 northern and 4 Southern Hemisphere influenza seasons. The study was performed in compliance with the principles of the Declaration of Helsinki and its amendments, and in accordance with Good Clinical Practice. The study protocol and amendments were approved by independent ethics committees and institutional review boards at each centre.

### 2.2 Patient inclusion and virological analysis

During this study period, the criteria for inclusion were as previously described. Briefly, patients >1 year of age, presenting within 48 hours after disease onset of influenza-like illness and/or a positive rapid test result for influenza were eligible for enrolment. Patients had throat or nasal swabs collected on days 1, 3 (self-swab), 6 and 10 for real-time reverse transcription PCR (RT-PCR) analyses of influenza type, subtype and susceptibility to NAI. NAI susceptibility was determined according to the IC_{50} values performed on the viruses by a chemiluminescent assay (NA-Star), and the measure of the fold increase observed as compared to IC_{50} values of susceptible strains, according to the common procedure. Resistant viruses were either with a reduced inhibition (RI) or a highly reduced inhibition (HRI), depending on the fold increase as per the WHO GISRS guidelines. The Day 10 evaluation was added to the protocol by an amendment in Year 2 of the study (2009). In cases of detection of resistance (by RT-PCR or by NAI assay), the viral load of both susceptible and resistant genotypes was compared through specific RT-PCR allowing the semi-quantification of wild-type and resistance-associated substitution at positions 275 for A(H1N1) viruses and 119 and 292 for A(H3N2) viruses. Similarly, the RT-PCR for the virus detection allowed virus quantification and respective loads estimations. Patients with mixed influenza A/influenza B and influenza A H1N1/influenza A H3N2 infections were excluded from the analysis. In addition, even if recruitment following previous NAI treatment was allowed, patients with previous NAI treatment were excluded from the analysis.

All Influenza-positive samples by RT-PCR were cultured on MDCK cells, and subsequently sequenced (haemagglutinin [HA] and neuraminidase [NA] gene segments) and phenotypically tested for NAI resistance when possible, as previously described.

### 2.3 Patient clinical follow-up

Scores for 7 cardinal influenza symptoms (0 [absent], 1 [mild], 2 [moderate], 3 [severe]) were recorded daily on diary cards by the patient (fever, sore throat, nasal congestion, cough, myalgia, fatigue and headache), checked by the physician (days 1-10), and summed to produce a total symptom score as previously described.

### 2.4 Biostatistical analysis

Kaplan-Meier plots were generated for time to viral RNA clearance and time to resolution of all diary card symptoms (no single symptom score of >1 on diary card). The statistical analysis was carried out by either Kruskal-Wallis or Wilcoxon signed-rank tests.

## RESULTS

During the 5-year surveillance period, 3230 patients with a single influenza strain infection were recruited. All study centres enrolled...
patients, the majority of whom (75.3%) were from the Northern Hemisphere (Figure 1). Of 3230 RT-PCR-positive patients, 2316 had influenza A and 914 had influenza B. These latter B cases are not analysed in this study report. In addition, some patients were excluded because of mixed influenza A and B infection, previous oseltamivir treatment or missing data.

Among the 2316 influenza A-positive patients registered, 2147 were eligible for analysis and 1216 received oseltamivir monotherapy (52.5%) within 2 days of symptom onset (9 seasonal H1N1; 662 H3N2; 545 H1N1pdm2009) (Figure 2: Flow chart).

Except for the 30 patients with the naturally resistant seasonal H1N1 included in 2008/9 (9 treated and 21 non-treated), antiviral resistance was detected by mutation-specific RT-PCR in Day 1 viruses from neither the 1207 treated patients nor the 910 non-treated patients. However, emergence of resistance (post-Day 1) was detected by RT-PCR in 43/1207 of the oseltamivir-treated influenza A H1N1pdm09 or H3N2 patients (Figure 2: Flow chart). Most of these patients had a mixed susceptible/resistant genotype (Tables 1a,b, 2a and b).

As reported previously, the detection of resistance was significantly more frequent in the 1- to 5-year-old age group as compared with the combined older age groups (30/253 [11.85%] vs 13/909[1.43%; P < .0001; Table 2). This was also observed when comparing the rate of resistance by subtype (16.1% vs 1.7% for H1N1pdm09 and 7.7% vs 1.2% for H3N2). In addition, we observed an increase in detection of resistant influenza A viruses in the last 3 years, for both H3N2 (2/190 [1.05%]; 4/97 [4.1%] and 10/326 [3%] in 2010/2011, 2011/2012 and 2012/2013, respectively) and H1N1pdm09 (14/226 [6.2%]; 1/26 [3.8%] and 9/57 [15.8%] in 2010/2011, 2011/2012 and 2012/2013, respectively), as compared with 0% (0/22) for H3N2 and 2/218 (0.9%) for H1N1pdm09 during the first 2 years of surveillance (Table 1a and b). The increased resistance in H3N2 viruses observed in the 3 last years, when the H3N2 incidence was higher, correlated with the emergence of strains with V241/N369K in NA combined with D114N/S202D/S468N in the HA of H3 (data not shown). Overall, these changes in the NA and HA were related to the emergence of the new 3C clade in 2011 (i.e A/Victoria/361/2011).

All 43 resistant viruses had acquired either the H275Y substitution for N1 viruses (n = 27) or the R292K substitution for N2 viruses (n = 16). No other substitutions known to be associated with reduced sensitivity to NA in human influenza viruses were detected when the Na-gene segment was sequenced from viruses obtained in culture on MDCK cells (i.e substitutions at positions E119, Q136, N142, T156 + D213, D198, I222, N294 and G320, sequence data not shown).

In 27/43 (62.8%) of samples in which resistance first appeared, viral loads were too low for phenotyping (Table 2a and b). Phenotypic characterization was performed on 16 resistant viruses, including 11 H1N1pdm2009 and 5 H3N2. In 7 cases (5 H1N1pdm09 and 2 H3N2), the phenotypic characterization did not show IC50 values associated with either RI or HRI, likely because of mixed sensitive/resistant populations (IC50 ranging from 0.1 to 7.6 nmol L−1, Table 2a and b).

In a significant number of cases (24/27 H1N1pdm2009 and 15/16 H3N2), the resistant virus detected by the mutation-specific RT-PCR, contained a mixed population of H275/Y275 or R292/K292 for at least one time point (Table 2a and b). In 22 of these cases (11 H1N1pdm2009 and 11 H3N2), only the last PCR-positive specimen was with a resistant profile with a mixed S/R genotype.

During follow-up, 11 of the 43 patients (9/27 H1N1pdm2009 and 2/16 H3N2) were still RT-PCR positive at Day 10 (as shown in Tables 2 and 2b). Pairwise comparison of the 3 study groups (treated, non-treated and treated but with a resistant virus) showed that viral RNA was detected for longer periods of time in nasal swabs samples collected from patients infected with oseltamivir-resistant viruses suggesting a delayed

**FIGURE 1** Geographic distribution and patient recruitment during years 1 to 5 of the IRIS study. IRIS, the Influenza Resistance Information Study
virus clearance, with a median of 8.1 days for the treated patients vs 9.9 days for the non-treated patients ($P < .0001$) and 10.9 days for the treated patients with a resistant virus ($P < .0001$) (Figure 3).

Similarly, the time to alleviation of symptoms was 1 day shorter in treated patients as compared with non-treated patients ($P < .0001$, see Figure 4). However, despite the delayed virus clearance observed in patients infected with oseltamivir-resistant viruses, this group exhibited a shorter duration of symptoms (borderline significance: $P = .024$, Figure 4). Resistant viruses emerged during the treatment course. In all documented cases, the resistant virus remained detectable until the last positive detection, except for one H1N1pdm2009 (patient 11 Table 2a) and 2 H3N2 cases that had a resistant genotype at Day 3 and Day 6, respectively, and a restored susceptible genotype detectable at Day 10 (patients 9 and 10 Table 2b).

4 | DISCUSSION

In years 1-5 of the IRIS study, resistance to oseltamivir in influenza A viruses was not detected in the 2316 Day 1 samples analysed (except
for one patient that was excluded because of prior antiviral treatment, and 30 patients with the naturally resistant seasonal H1N1). This low rate of detection is consistent with the literature and recent reports from WHO, where resistance in initial samples is rarely reported.\(^{15,17-19}\) This oseltamivir resistance was detected only in specimens collected during the course of antiviral treatment, and mostly in patients aged 1-5 years. Among 1207 patients with influenza A H1N1pdm09 and H3N2 viruses that have been investigated, resistance was observed in 27 H1N1pdm09 and 16 H3N2 viruses, with the H275Y and R292K substitutions only, respectively, representing 3.89% of the patients. In most cases, resistance was associated with a mixed susceptible/resistant virus population, reflecting a progressive selection of the resistant population during treatment. Besides H275Y and R292K, no other substitution associated with resistance was detected in the NA. This suggests that as opposed to observations in immunocompromised, these 2 positions are almost the exclusive “hot spots” for changes associated with antiviral resistance in the context of oseltamivir pressure in immunocompetent patients.\(^{14,20}\)

In our study, the proportion of R292K substitutions in H3N2 viruses isolated (16/662, 2.4%) was relatively low as compared to Kiso et al.\(^{21}\) The latter reported 9/50 (18%) of emerging resistant viruses during treatment in children with a first detection at day 3 of treatment. In our study, we report only 7.7% (10/129) of emerging resistance. This difference may be due to the recruitment of cases (majority of hospital cases in the Kiso study), the sampling procedures (nasal washes in some patients of the Kiso study vs swabs in our study) and the geographical distribution of our patients. However, we both support the idea that monitoring the resistance of influenza viruses requires analysis of sequential specimens collected in patients treated with oseltamivir. Surveillance with D1 samples only cannot provide a clear picture for an emerging resistance risk assessment, especially for H3N2 viruses.

According to analysis of the sequential specimens collected in these patients, resistant viruses emerged by Day 3 of treatment from susceptible strains and were selected by oseltamivir. It is known that the fitness of R292K H3N2 viruses is putatively severely impaired.\(^{22}\) This detection of the R292K substitution was performed by a specific snip RT-PCR, a sensitive method that can detect down to 5% of a minority species.\(^{15}\) It confirmed also that in most cases, a mixed population is detected, supporting the hypothesis that impaired NA activity of R292K viruses may be trans-complemented by the NA activity of R292 bystander viruses, as it has been reported for mutations at position 119.\(^{23}\) The mutation-specific real-time RT-PCR used in the current study and HA or NA sequencing were performed on the original clinical specimen and not culture based or genetically assessed by sequencing on culture material. In the present study, of the 16 samples in which the R292K mutation was detected, only 5 could be cultured and subsequently tested phenotypically for NAI susceptibility. Two of them showed an increased IC50, while 3 had a normal IC50. This lack of detection of reduced inhibition may be due to the use of the Na- Star system (chemiluminescent assay) that is less sensitive than the gold standard MUNANA-based fluorescent assay.\(^{24}\)

The H275Y resistance in H1N1pdm09 was the most reported in this study (27/43 R-Viruses). This is consistent with the various reports about oseltamivir resistance in N1 viruses in general. This resistance emerged from Day 3 in 1/3 of the 27 cases, not only in children (Table 2b). When, measured, the IC50 values were mostly reduced inhibition, and some were normal inhibition, due to mixed genotypes (H275 & 275Y) and the use of the chemiluminescent assay. The

| TABLE 1 | Resistance mutations detected by RT-PCR in the 1207 influenza A-positive patients treated with oseltamivir, by study year and age group. (a) H1N1pdm09; (b) H3N2 |
|----------|-------------------------------------------------------------------------------------------------------------------------------------|
| **Age group (y)** | **Detection frequency of H275Y substitution n/N (%)\(^a\)** | **Negative RT-PCR at Day 10 for H275Y viruses** | **Resistance rate (%)** |
| 2008-10 | 2010-11 | 2011-12 | 2012-13 | 2010-11 | 2011-12 | 2012-13 |
| a | | | | | | | |
| 1-5 | 1/48 (2.1) | 12/53 (22.6) | 1/5 (20.0) | 6/18 (33.3) | 15/20 | 20/124 (16.1) |
| 6-12 | 0/75 (0.0) | 1/30 (3.3) | 0/6 (0.0) | 1/4 (25.0) | 2/2 | 2/115 (1.7) |
| ≥13 | 1/95 (1.1) | 2/143 (1.4) | 0/15 (0.0) | 2/35 (5.7) | 2/5 | 5/288 (1.7) |
| NA | | | | | 0/18 (0) |
| **Age group (y)** | **Detection frequency of R292K substitution n/N (%)\(^a\)** | **Negative RT-PCR at Day 10 for R292K viruses** | **Resistance rate (%)** |
| 2008-10 | 2010-11 | 2011-12 | 2012-13 | 2010-11 | 2011-12 | 2012-13 |
| b | | | | | | | |
| 1-5 | 0/1 (0.0) | 1/36 (2.8) | 2/16 (12.5) | 7/76 (9.2) | 1/10 | 10/129 (7.7) |
| 6-12 | 0/1 (0.0) | 0/42 (0.0) | 2/15 (13.3) | 1/76 (1.3) | 1/3 | 3/134 (2.2) |
| ≥13 | 0/20 (0.0) | 1/112 (0.9) | 0/66 (0.0) | 2/174 (1.2) | 0/3 | 3/372 (0.8) |
| NA | | | | | 0/27 (0) |

n/N (%), number of viruses with mutation/Number of viruses tested (percentage). NA missing data (age group and year of detection).

\(^a\)The 9 patients with A(H1N1)s virus are not listed in this table.
**TABLE 2**  Analysis of the kinetic of emergence of genotypic and phenotypic resistance during the study. (a) kinetics of emergence of the H275Y substitution in H1N1pdm09 viruses as detected by specific RT-PCR and measure of IC50 values, (b) kinetics of emergence of the R292K substitution and screening for E119V substitution in H3N2 viruses as detected by specific RT-PCR and measure of IC50 values.

| Patient | Year  | Age | Visit   | Virus load (log) | H275 | 275Y | IC50 to oseltamivir |
|---------|-------|-----|---------|------------------|------|------|---------------------|
| a       |       |     |         |                  |      |      |                     |
| 1       | 2009  | 13  | Baseline| 5.6              | x    |      | NA                  |
|         |       |     | Day 3   | 3.7              | x    |      |                     |
|         |       |     | Day 6   | ND               |      |      |                     |
|         |       |     | Day 10  | ND               |      |      |                     |
| 2       | 2011  | 4   | Baseline| 6.6              | x    |      |                     |
|         |       |     | Day 3   | 4.1              | x    |      |                     |
|         |       |     | Day 6   | 2.8              | x    | x    | NA                  |
|         |       |     | Day 10  | ND               |      |      |                     |
| 3       | 2011  | 1   | Baseline| 5.7              | x    |      |                     |
|         |       |     | Day 3   | 4.5              | x    | x    | NA                  |
|         |       |     | Day 6   | 3.7              |      | x    |                     |
|         |       |     | Day 10  | ND               |      |      |                     |
| 4       | 2011  | 14  | Baseline| 6                | x    |      |                     |
|         |       |     | Day 3   | 4.7              | x    |      |                     |
|         |       |     | Day 6   | 3.8              | x    | x    | 130 nmol L^{-1}     |
|         |       |     | Day 10  | ND               |      |      |                     |
| 5       | 2010  | 3   | Baseline| 6.3              | x    |      |                     |
|         |       |     | Day 3   | 5.9              | x    |      |                     |
|         |       |     | Day 6   | 4.5              |      | x    |                     |
|         |       |     | Day 10  | 3.8              | x    | x    | 68 nmol L^{-1}      |
| 6       | 2011  | 1   | Baseline| 5.4              | x    |      |                     |
|         |       |     | Day 3   | 5.6              | x    |      |                     |
|         |       |     | Day 6   | 4.2              | x    | x    | 74 nmol L^{-1}      |
|         |       |     | Day 10  | 4.4              | x    | x    | 79 nmol L^{-1}      |
| 7       | 2011  | 6   | Baseline| 6.8              | x    |      |                     |
|         |       |     | Day 3   | 5.1              | x    |      |                     |
|         |       |     | Day 6   | 2.1              |      | x    |                     |
|         |       |     | Day 10  | 3.0              | x    | x    | NA                  |
| 8       | 2011  | 1   | Baseline| 5.4              | x    |      |                     |
|         |       |     | Day 3   | 1.5              | x    |      |                     |
|         |       |     | Day 6   | 3.9              | x    | x    | 0.56 nmol L^{-1}    |
|         |       |     | Day 10  | ND               |      |      |                     |
| 9       | 2012  | 1   | Baseline| 5.8              | x    |      |                     |
|         |       |     | Day 3   | 4.6              | x    |      |                     |
|         |       |     | Day 6   | x                |      | x    | NA                  |
|         |       |     | Day 10  | ND               |      |      |                     |
| 10      | 2013  | 4   | Baseline| 5.9              | x    |      |                     |
|         |       |     | Day 3   | 4.5              | x    |      |                     |
|         |       |     | Day 6   | 6.0              | x    | x    | 100 nmol L^{-1}     |
|         |       |     | Day 10  | ND               |      |      |                     |

(Continues)
| Patient | Year | Age | Visit | Virus load (log) | H275 | 275Y | IC<sub>50</sub> to oseltamivir |
|---------|------|-----|-------|-----------------|------|------|-------------------------------|
| 11      | 2013 | 6   | Baseline | 7.5            | x    |      | NA                            |
|         |      |     | Day 3   | 5.7            | x    | x    | NA                            |
|         |      |     | Day 6   | 4.5            | x    | x    | NA                            |
|         |      |     | Day 10  | 3.6            | x    |      | NA                            |
| 12      | 2009 | 1   | Baseline | 7.2            | x    |      | NA                            |
|         |      |     | Day 3   | 4.5            | x    | x    | NA                            |
|         |      |     | Day 6   | ND             |      |      | NA                            |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 13      | 2011 | 2   | Baseline | 4.3            | x    |      | NA                            |
|         |      |     | Day 3   | 3.0            | x    |      | NA                            |
|         |      |     | Day 6   | 1.8            | x    | x    | NA                            |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 14      | 2012 | 38  | Baseline | 4.0            | x    |      | NA                            |
|         |      |     | Day 3   | 4.0            | x    | x    | NA                            |
|         |      |     | Day 6   | 2.6            | x    |      | NA                            |
|         |      |     | Day 10  | 2.4            | x    |      | NA                            |
| 15      | 2012 | 2   | Baseline | 5.5            | x    |      | NA                            |
|         |      |     | Day 3   | 2.0            | x    |      | NA                            |
|         |      |     | Day 6   | 1.9            | x    |      | NA                            |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 16      | 2012 | 1   | Baseline | 5.1            | x    |      | BA 0.36 nmol L<sup>-1</sup>   |
|         |      |     | Day 3   | 4.7            | x    | x    | BA 0.36 nmol L<sup>-1</sup>   |
|         |      |     | Day 6   | 3.6            | x    | x    | 0.36 nmol L<sup>-1</sup>     |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 17      | 2011 | 1   | Baseline | 7.2            | x    |      | NA                            |
|         |      |     | Day 3   | 4.3            | x    |      | NA                            |
|         |      |     | Day 6   | 4.3            | x    | x    | 7.6 nmol L<sup>-1</sup>      |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 18      | 2012 | 2   | Baseline | 5.4            | x    |      | NA                            |
|         |      |     | Day 3   | 4.2            | x    |      | NA                            |
|         |      |     | Day 6   | 4.0            | x    | x    | NA                            |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 19      | 2013 | 3   | Baseline | 4.0            | x    |      | NA                            |
|         |      |     | Day 3   | 5.5            | x    |      | NA                            |
|         |      |     | Day 6   | 4.0            | x    | x    | 93 nmol L<sup>-1</sup>      |
|         |      |     | Day 10  | ND             |      |      | NA                            |
| 20      | 2013 | 55  | Baseline | 4.6            | x    |      | NA                            |
|         |      |     | Day 3   | 5.1            | x    |      | NA                            |
|         |      |     | Day 6   | 5.5            | x    | x    | 86 nmol L<sup>-1</sup>      |
|         |      |     | Day 10  | 2.7            | x    | x    | NA                            |

(Continues)
### Table 2 (Continued)

| Patient | Year | Age | Visit   | Virus load (log) | H27S | 275Y | IC\textsubscript{50} to oseltamivir |
|---------|------|-----|---------|------------------|------|------|----------------------------------|
| 21      | 2011 | 2   | Baseline| 6.8              | x    | x    | NA                               |
|         |      |     | Day 3   | 5.7              | x    |      | NA                               |
|         |      |     | Day 6   | 3.0              |     | x    | NA                               |
|         |      |     | Day 10  | 3.1              |     | x    | NA                               |
| 22      | 2011 | 55  | Baseline| 6.6              | x    |      | NA                               |
|         |      |     | Day 3   | 4.6              |     | x    | NA                               |
|         |      |     | Day 6   | ND               |     |      | NA                               |
|         |      |     | Day 10  | ND               |     |      | NA                               |
| 23      | 2011 | 3   | Baseline| 5.7              | x    |      | NA                               |
|         |      |     | Day 3   | 6.1              | x    |      | NA                               |
|         |      |     | Day 6   | 3.1              |     | x    | NA                               |
|         |      |     | Day 10  | ND               |     |      | NA                               |
| 24      | 2011 | 5   | Baseline| 6.6              | x    |      | NA                               |
|         |      |     | Day 3   | 2.9              | x    |      | NA                               |
|         |      |     | Day 6   | 4.7              |     | x    | NA                               |
|         |      |     | Day 10  | 1.6              |     | ?    | NA                               |
| 25      | 2011 | 1   | Baseline| 2.7              | x    |      | NA                               |
|         |      |     | Day 3   | 5.5              |     | x    | 1.1 nmol L\textsuperscript{-1}   |
|         |      |     | Day 6   | 6.2              |     | x    | 53 nmol L\textsuperscript{-1}   |
|         |      |     | Day 10  | ND               |     |      | NA                               |
| 26      | 2011 | 1   | Baseline| 5.7              | x    |      | NA                               |
|         |      |     | Day 3   | 5.7              | x    |      | NA                               |
|         |      |     | Day 6   | 5.4              |     | x    | 53 nmol L\textsuperscript{-1}   |
|         |      |     | Day 10  | ND               |     |      | NA                               |
| 27      | 2011 | 4   | Baseline| 6.0              | x    |      | NA                               |
|         |      |     | Day 3   | 3.4              | x    |      | NA                               |
|         |      |     | Day 6   | 3.3              |     | x    | NA                               |
|         |      |     | Day 10  | x                |     |      | NA                               |

### Table 2 (Continued)

| Patient | Year | Age | Visit   | Virus load (log) | 119E | R292 | 292K | IC\textsubscript{50} to oseltamivir |
|---------|------|-----|---------|------------------|------|------|------|----------------------------------|
| 1       | 2011 | 2   | Baseline| 7.7              | x    | x    | x    | NA                               |
|         |      |     | Day 3   | 3.8              | x    | x    | x    | NA                               |
|         |      |     | Day 6   | 4.1              | x    | x    | x    | NA                               |
|         |      |     | Day 10  | ND               |      |      |      | NA                               |
| 2       | 2012 | 4   | Baseline| 5.4              | x    | x    | x    | NA                               |
|         |      |     | Day 3   | 5.7              | x    | x    | x    | NA                               |
|         |      |     | Day 6   | 4.9              | x    | x    | x    | NA                               |
|         |      |     | Day 10  | ND               |      |      |      | NA                               |
| 3       | 2013 | 2   | Baseline| 5.5              | x    | x    | x    | NA                               |
|         |      |     | Day 3   | 4.5              | x    | x    | x    | NA                               |
|         |      |     | Day 6   | 3.6              | x    | x    | x    | NA                               |
|         |      |     | Day 10  | ND               |      |      |      | NA                               |
| Patient | Year | Age | Visit | Virus load (log) | 119E | R292 | 292K | IC₅₀ to oseltamivir |
|---------|------|-----|-------|------------------|------|------|------|-------------------|
| 4       | 2012 | 4   | Baseline | 6.2 | x | x | | |
|         |      |     | Day 3     | 6.3 | x | x | | |
|         |      |     | Day 6     | 4.8 | x | x | x | >1000 nmol L⁻¹ |
|         |      |     | Day 10    | ND  |   |   |   | |
| 5       | 2012 | 66  | Baseline  | 4.4 | x | x | | |
|         |      |     | Day 3     | 4.0 | x | x | | |
|         |      |     | Day 6     | 3.7 | x | x | x | NA |
|         |      |     | Day 10    | ND  |   |   |   | |
| 6       | 2013 | 4   | Baseline  | 5.1 | x | x | | |
|         |      |     | Day 3     | 4.0 | x | x | | |
|         |      |     | Day 6     | 2.5 | x | x | x | NA |
|         |      |     | Day 10    | ND  |   |   |   | |
| 7       | 2010 | 20  | Baseline  | 4.5 | x | x | | |
|         |      |     | Day 3     | 3.6 | x | x | x | NA |
|         |      |     | Day 6     | ND  |   |   |   | |
|         |      |     | Day 10    | ND  |   |   |   | |
| 8       | 2011 | 7   | Baseline  | 4.7 | x | x | | |
|         |      |     | Day 3     | 2.7 | x | x | | |
|         |      |     | Day 6     | 3.1 | x | x | x | NA |
|         |      |     | Day 10    | ND  |   | x | x | |
| 9       | 2012 | 6   | Baseline  | 7.7 | x | x | | |
|         |      |     | Day 3     | 3.9 | x | x | | |
|         |      |     | Day 6     | 4.2 | x | x | x | NA |
|         |      |     | Day 10    | 3.9 |   |   |   | |
| 10      | 2012 | 3   | Baseline  | 5.2 | x | x | | |
|         |      |     | Day 3     | 4.5 | x | x | | |
|         |      |     | Day 6     | 4.8 | x | x | x | 0.29 nmol L⁻¹ |
|         |      |     | Day 10    | 3.0 | x | x | | |
| 11      | 2012 | 41  | Baseline  | 6.8 | x | x | | |
|         |      |     | Day 3     | 3.3 | x | x | x | NA |
|         |      |     | Day 6     | ND  |   |   |   | NA |
|         |      |     | Day 10    | ND  |   |   |   | |
| 12      | 2012 | 4   | Baseline  | 5.9 | x | x | | |
|         |      |     | Day 3     | 4.1 | x | x | | |
|         |      |     | Day 6     | 5.5 | x | x | x | >1000 nmol L⁻¹ |
|         |      |     | Day 10    | ND  |   |   |   | |
| 13      | 2012 | 7   | Baseline  | 5.9 | x | x | | |
|         |      |     | Day 3     | 4.5 | x | x | | |
|         |      |     | Day 6     | 3.3 | x | x | x | NA |
|         |      |     | Day 10    | ND  |   |   |   | |
| 14      | 2012 | 2   | Baseline  | 6.4 | x | x | | |
|         |      |     | Day 3     | MISS|   |   |   | |
|         |      |     | Day 6     | 3.9 | x | x | x | 0.1 nmol L⁻¹ |
|         |      |     | Day 10    | ND  |   |   |   | |

(Continues)
resistant Brisbane H1N1 that emerged in 2008 was supposed to be related to structural changes in the backbone of the NA that facilitated (imposed) the introduction of 275Y in the NA pocket to maintain both virus fitness and HA-NA balanced activities. In our study, the frequency of detection of resistance due to a 275Y substitution gradually increased during the surveillance, but the limited number of cases makes any interpretation difficult. According to the studies performed recently, it seems that this path to a sustained 275Y virus in H1N1pdm09 as observed in 2008 for the Brisbane-like H1N1 has not started, but should be monitored.

Post-treatment emergence of resistance in H1N1pdm09 appeared to be more frequent in the last 3 years, although with no statistically significant trend, possibly attributed to insufficient statistical power. This increase in resistance observed for H3N2 viruses cannot be determined because of the limited number of patients enrolled in the 2 first years. The apparent increase of 292K in the 2 most recent years coincided with the detection globally of a new 3C H3N2 clade. Whether HA or NA mutations of the new clade 3C viruses that emerged during the 2011 influenza season relative to earlier Influenza A H3N2 clades increase the replicative capacity of R292K containing

**Figure 3** Time (days) from symptom onset to first laboratory record with influenza A RNA not detected. Pairwise comparisons between patients with no treatment vs patients treated with oseltamivir (within 48 hours of symptom onset) and vs treated patient with a resistant virus. Both treated and untreated populations included patients infected by influenza A viruses, with no detection of resistant viruses. The 49 resistant patients comprise 40 patients infected with H3N2 or H1N1pdm09 who developed resistance during the study plus 9 patients infected with seasonal H1N1. All 49 patients were in the treated group. Three patients (2 with H1N1pdm09 and one with H3N2) developed oseltamivir resistance during the study but were not treated until Day 3. These patients are not included in this comparison as they do not meet the definition

### Table 2 (Continued)

| Patient | Year | Age | Visit | Virus load (log) | 119E | R292 | 292K | IC50 to oseltamivir |
|---------|------|-----|-------|-----------------|------|------|------|-------------------|
| 15      | 2011 | 3   | Baseline | 5.7            | x    | x    | x    | NA                |
|         |      |     | Day 3  | 4.3            | x    | x    | x    |                   |
|         |      |     | Day 6  | 3.7            | x    | x    | x    |                   |
|         |      |     | Day 10 | ND             |      |      |      |                   |
| 16      | 2011 | 2   | Baseline | 5.8            | x    | x    | x    | 0.52 nmol L⁻¹      |
|         |      |     | Day 3  | 3.3            | x    | x    | x    |                   |
|         |      |     | Day 6  | 5.5            | x    | x    | x    |                   |
|         |      |     | Day 10 | ND             |      |      |      |                   |

NA, Not available (missing specimen); Neg, Influenza detection negative; NC, Not cultured or culture failed because of low viral load by RT-PCR (Ct>32). IC50 values were obtained from virus culture and determined as oseltamivir concentration inhibiting NA activity as measured by a chemiluminescent assay (NA-Star), as described in the material and methods.
viruses similar to V241I/N369K in 2009pdmH1N1 for H275Y remains to be investigated. Similarly, there are no clues about Ha or Na substitution that would increase the replicative capacity of 275Y containing H1N1pdm09 viruses.

Last, our results can also suggest a reduced risk of transmission a NAI-resistant virus when this resistance is developed during treatment. We could document that, in most cases of this study, resistance was observed only in the last positive clinical specimen (30/43), when the viral load was significantly low. We can speculate that the risk of transmission is correlated with the viral shedding and concentration at the site of replication. So, even if we also observed that virus detection (and shedding) was longer as compared with non-treated and treated patients (Figure 3), the risk of transmission of a resistant virus may be low.

This IRIS study is unique in providing a follow-up of resistance in a large population with direct and sensitive screening of clinical specimens. Compared with other studies that have analysed the susceptibility of influenza viruses at treatment onset, it provides detailed data on the risk of emergence of resistance in immunocompetent patients, with some hints regarding the possible emergence of resistance in viruses that display a genetic background favouring this emergence and its sustainability.

This study also confirms the lack of correlation between decreases in viral load and clinical outcome, especially when a resistant virus emerges.

**ACKNOWLEDGEMENTS**

The authors would like to acknowledge the support of all the IRIS investigators and the clinical study management team at Roche and Micron Research: Laura Burleigh, Andy Kenwright, Isabel Najera and James Smith (Roche); Ian Harding, Miriam O’Hare, Russell Outlaw, Vaughan Reed and Derek Griffiths (Micron). The IRIS study was funded by F. Hoffmann-La Roche Ltd.

**CONFLICT OF INTERESTS**

B. L. has served as consultant to and received support for travel from Roche. All personal remuneration stopped in September 2010. C. B. has served as consultant to Roche and is an employee of Erasmus MC which received a grant and support for travel, review and other consultant activities from Roche. A. M. has received consultancy fees and support for travel from Roche. J. N.-V.-T. has served on speaker bureau for, served as a consultant to, and received grants and support for travel from Roche and GlaxoSmithKline, but all personal remuneration stopped in September 2010. He has also received support for travel from and currently receives other research funding from Roche. The research activities of A.O. of Erasmus MC for the IRIS study are funded by Roche. He is CSO of Viroclinics Biosciences BV, a spin out of Erasmus MC that collaborates with pharma industry. He is a board member of Protein Sciences and is an advisor to pharma companies on an ad hoc basis. M. S. has served as consultant to, and received a
grant and support for travel from Roche. R. J. W. serves on the board of directors of Gilead Sciences (originators of oseltamivir). The above authors are members of the IRIS Advisory Board. JSN-V-T is a named author on this manuscript and EIC of Influenza and other respiratory viruses. However all Editorial processes and decisions relating to this manuscript were handled independently by Dr. Rebecca Jane Cox, Associate Editor. JSN-V-T played no role in any decisions related to revision or acceptance of the manuscript.

**ORCID**

**Bruno Lina** http://orcid.org/0000-0002-8959-2123

**REFERENCES**

1. Hayden FG, Pavia AT. Antiviral management of seasonal and pandemic influenza. J Infect Dis. 2006;194:119-26.
2. Kim CU, Lew W, Williams MA, et al. Influenza neuraminidase inhibitors possessing a novel hydrophobic interaction in the enzyme active site: design, synthesis and structural analysis of carbocyclic sialic acid analogues with potent anti-influenza activity. J Am Chem Soc. 1997;119:681-90.
3. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-81.
4. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395-402.
5. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12:603-16.
6. Stephenson I, Democratis J, Lackenby A, et al. Neuraminidase inhibitor resistance after oseltamivir treatment of acute influenza A and B in children. Clin Infect Dis. 2009;48:389-96.
7. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
8. Hauge SH, Dudman S, Borgen K, Lackenby A, Hungnes O. Oseltamivir-resistant influenza viruses A (H1N1), Norway, 2007-08. Emerg Infect Dis. 2009;15:155-62.
9. Centers for Disease Control and Prevention. Update: influenza activity—United States, September 28, 2008—April 4, 2009, and composition of the 2009–10 influenza vaccine. MMWR Morb Mortal Wkly Rep. 2009;58:369-74.
10. Meijer A, Lackenby A, Hungnes O, et al. Oseltamivir-resistant influenza virus A (H1N1), Europe, 2007–08 season. Emerg Infect Dis. 2009;15:552-60.
11. Rameix-Welti MA, Enouf V, Cuvelier F, Jannin P, van der Werf S. Enzymatic properties of the neuraminidase of seasonal H1N1 influenza viruses provide insights for the emergence of natural resistance to oseltamivir. PloS Pathog. 2008;4:e1000103.
12. World Health Organization (WHO). Update on oseltamivir-resistant pandemic (H1N1) 2009 influenza virus: January 2010. Wkly Epidemiol Rec. 2010;85:37-48.
13. Whitley RJ, Boucher CA, Lina B, et al. Global assessment of resistance to neuraminidase inhibitors, 2008–2011: the Influenza Resistance Information Study (IRIS). Clin Infect Dis. 2013;56:1197-205.
14. Pozo F, Lina B, Andrade HR, et al., Community Network of Reference Laboratories for Human Influenza in Europe. Guidance for clinical and public health laboratories testing for influenza virus antiviral drug susceptibility in Europe. J Clin Virol. 2013;57:5-12.
15. Meijer A, Rebeļo-de Andrade H, Correia V, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2012–2013. Antiviral Res. 2014;110:31-41.
16. van der Vries E, Anber J, van der Linden A, et al. Molecular assays for quantitative and qualitative detection of influenza virus and oseltamivir resistance mutations. J Mol Diagn. 2013;15:347-54.
17. Tashiro M, McKimm-Breschkin JL, Saito T, et al. Surveillance for neuraminidase-inhibitor-resistant influenza viruses in Japan, 1996–2007. Antivir Ther. 2009;14:751-61.
18. Hurt AC, Besselaar TG, Daniels RS, et al. Global update on the susceptibility of human influenza viruses to neuraminidase inhibitors, 2014–2015. Antiviral Res. 2016;132:178-85.
19. Sheu TG, Deyde VM, Okomo-Adhiambo M, et al. Surveillance for neuraminidase inhibitor resistance among human influenza A and B viruses circulating worldwide from 2004 to 2008. Antimicrob Agents Chemother. 2008;52:3284-92.
20. Hussain M, Galvin HD, Haw TY, Nutsford AN, Husain M. Drug resistance in influenza A virus: the epidemiology and management. Infect Drug Resist. 2017:10:121-134.
21. Kiso M, Mitamura K, Sakai-Tagawa Y, et al. Resistant influenza A viruses in children treated with oseltamivir: descriptive study. Lancet. 2004;364:759-65.
22. Yen HL, Herlocher LM, Hoffmann E, et al. Neuraminidase inhibitor-resistant influenza viruses may differ substantially in fitness and transmissibility. Antimicrob Agents Chemother. 2005;49:4075-84.
23. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother. 2010;54:1834-41.
24. Wetherall NT, Trivedi T, Zeller J, et al. Evaluation of neuraminidase enzyme assays using different substrates to measure susceptibility of influenza virus clinical isolates to neuraminidase inhibitors: report of the neuraminidase inhibitor susceptibility network. J Clin Microbiol. 2003;41:742-50.
25. Gaynard A, Le Briand N, Frobert E, Lina B, Escuret V. Functional balance between neuraminidase and haemagglutinin in influenza viruses. Clin Microbiol Infect. 2016;22:975-983.
26. Wang B, Taylor J, Ratnamohan M, et al. Frequency of oseltamivir-resistant influenza viruses in children treated with oseltamivir: descriptive study. J Clin Microbiol. 2006;44:3915-22.
27. Bloom JD, Gong LJ, Baltimore, D. Neuraminidase inhibitors: role in the evolution of influenza oseltamivir resistance. Science. 2010;328:1272-5.
28. Tewawong N, Prachayangprecha S, Vichiwattana P, et al. Assessing antigenic drift of seasonal influenza A(H3N2) and A(H1N1)pdm09 viruses. PLoS ONE. 2015;10:e0139958.

**How to cite this article:** Lina B, Boucher C, Osterhaus A, et al. Five years of monitoring for the emergence of oseltamivir resistance in patients with influenza A infections in the Influenza Resistance Information Study. Influenza Other Respi Viruses. 2018;00:1–12. https://doi.org/10.1111/irv.12534